Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Aug 30, 2011 11:32am
349 Views
Post# 18993347

good posts

good postsThanks for all the posts; For now, I would just like a new FDA panel date set. I have been saying all along that the share price would be between $1.50 and $2.00 just prior to the 10/14 meeting, and if that was the case today than we would see a huge sell off. Right now we are still under valued and it does give Diagnocure time to get here to the States and market their company, attract new investors prior to FDA approval.
     There were a number of posts that talked about the delay being due to the FDA process and I agree 100% with that now. (I know I posted about Panther and other tests, but this was not a delay due to GPRO, in due time it will run on Panther and also be included in a panel of other markers but for the time being its all the FDA)
 I want to add what I stated before that the FDA does know that this test will adopted rapidly and the concern is about intended usage and missed positive cases. They want to get it right because they know how big it is and the market size.
Maybe we will see a turn around today with new investors jumping in. By the way, GPRO never posted news about the upcoming meeting so they  will not formally release news related to the delay.
Bullboard Posts